July 2017  

Tangen Biosciences receives a Notice of Intent to fund the SBIR/NIH phase I grant application for Rapid Detection of Multiple Sepsis Pathogens.    

clinical trial only.JPG

April 2017  

Tangen Biosciences  holds Pre-Submission meeting with FDA to discuss parameters for the clinical testing of the TangenDx direct-from-blood Fungal Panel in support of a             planned 510(k) submission. 

clipboard check.jpg

February 2017  

Tangen Biosciences has commenced the process of securing FDA clearance for its novel molecular diagnostic platform by submitting a Pre-Submission Package to the Center for Devices and Radiological Health of the Food and Drug Administration.  

goal achieved.JPG

November 2016

 Tangen successfully demonstrates the TangenDx Fungal Sepsis Panel at three clinical microbiology labs in the northeast region. 


June 2016  

Tangen Biosciences, Inc., has been awarded a Phase I SBIR grant from the National Institutes of Health to develop a rapid molecular assay for the detection of Multiple Drug Resistant Mycobacteria Tuberculosis (MDR-TB) in sputum.  The grant will fund the development of specific primers to identify 15 different SNPs in the TB genome that confer resistance to front line TB antibiotics. The drug sensitivity test will be added into the existing Tangen TB assay to create a panel that will include accurate diagnosis of TB along with comprehensive drug sensitivity information.  The MDR-TB assay panel will run on a single disposable disk in the TangenDx Instrument, a battery powered, portable, low cost, highly sensitive and simple to use molecular diagnostic platform. 


January 2016  

Tangen Biosciences is selected to present and Cavendish Global Impact Forum  Press Release


Dec 2015

Tangen completes $2MM Seed Round equity financing


 Oct 2015

Tuberculosis article:


June 2015  

Tangen completes first TB clinical sample trial and submits results to the Foundation for Innovative New Diagnostics for review.  System demonstrates sensitivity and specificity on par with the best state of the art molecular diagnostic systems.

clinical trial only.JPG

May 2015

Tangen begins first blind clinical sample trial for infectious Tuberculosis detection

key hire.jpg

January 2015  

Dr. Richard Carroll joins Tangen as VP of Business Development and Director of Clinical Affairs


December 2014  

Tangen secures $500k investment from the Connecticut Bioscience Innovation Fund (CBIF):


April 2014  

Tangen relocates to combined lab & office space at 780 East Main Street in Branford Connecticut


January 2014  

Tangen Biosciences secures Pre-Seed investment from Connecticut Innovations and Private angel investor